Codiak BioSciences, Inc. (CDAK) financial statements (2022 and earlier)
Company profile
| Business Address |
35 CAMBRIDGEPARK DRIVE CAMBRIDGE, MA 02140 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments, including: | 76,900 | 98,600 | 113,700 | 130,300 | 88,915 | 48,300 | ||
| Cash and cash equivalents | 76,938 | 98,584 | 113,681 | 130,272 | 88,915 | 48,339 | ||
| Other undisclosed cash, cash equivalents, and short-term investments | (38) | 16 | 19 | 28 | (39) | |||
| Prepaid expense | 2,593 | 2,598 | ||||||
| Deferred costs | 200 | 200 | 1,660 | |||||
| Other undisclosed current assets | 10,478 | 5,313 | 5,622 | 4,377 | 2,045 | 2,401 | ||
| Total current assets: | 90,171 | 103,913 | 119,322 | 134,677 | 93,758 | 52,361 | ||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 21,957 | 21,258 | 21,519 | 21,767 | 22,003 | 22,226 | ||
| Property, plant and equipment | 23,479 | 29,384 | 30,263 | 30,885 | 31,410 | 31,544 | ||
| Restricted cash and investments | 4,170 | 4,170 | 4,170 | 4,170 | 4,170 | 4,170 | ||
| Other noncurrent assets | 50 | |||||||
| Other undisclosed noncurrent assets | 31,893 | |||||||
| Total noncurrent assets: | 81,499 | 54,812 | 55,952 | 56,822 | 57,583 | 57,990 | ||
| TOTAL ASSETS: | 171,670 | 158,725 | 175,274 | 191,499 | 151,341 | 110,351 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 11,541 | 11,313 | 9,471 | 8,967 | 10,888 | 26,346 | ||
| Accounts payable | 1,838 | 1,998 | 1,782 | 2,162 | 2,018 | 2,488 | ||
| Accrued liabilities | 9,703 | 9,315 | 7,689 | 6,805 | 8,870 | 23,858 | ||
| Deferred revenue | 12,963 | 9,352 | 9,117 | 4,345 | 5,281 | 6,268 | ||
| Other undisclosed current liabilities | 2,661 | 2,438 | 2,333 | 2,230 | 1,482 | 1,778 | ||
| Total current liabilities: | 27,165 | 23,103 | 20,921 | 15,542 | 17,651 | 34,392 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 60,314 | 60,016 | 60,536 | 61,026 | 61,500 | 61,927 | ||
| Long-term debt, excluding current maturities | 25,430 | 25,352 | 25,230 | 25,095 | 24,960 | 24,825 | ||
| Operating lease, liability | 34,884 | 34,664 | 35,306 | 35,931 | 36,540 | 37,102 | ||
| Liabilities, other than long-term debt | 30,686 | 41,393 | 41,746 | 46,008 | 57,416 | 58,069 | ||
| Deferred revenue | 30,686 | 41,393 | 41,746 | 46,008 | 57,416 | 58,069 | ||
| Other undisclosed noncurrent liabilities | 207 | 207 | 207 | 207 | ||||
| Total noncurrent liabilities: | 91,000 | 101,616 | 102,489 | 107,241 | 119,123 | 119,996 | ||
| Total liabilities: | 118,165 | 124,719 | 123,410 | 122,783 | 136,774 | 154,388 | ||
| Temporary equity, carrying amount | 225,033 | |||||||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 53,505 | 34,006 | 51,864 | 68,716 | 14,567 | (269,070) | ||
| Common stock | 2 | 2 | 2 | 2 | 2 | |||
| Additional paid in capital | 378,750 | 375,913 | 372,069 | 367,112 | 302,655 | 1,063 | ||
| Accumulated deficit | (325,247) | (341,909) | (320,207) | (298,398) | (288,090) | (270,133) | ||
| Total stockholders' equity: | 53,505 | 34,006 | 51,864 | 68,716 | 14,567 | (269,070) | ||
| TOTAL LIABILITIES AND EQUITY: | 171,670 | 158,725 | 175,274 | 191,499 | 151,341 | 110,351 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 7,697 | 1,157 | 890 | 13,191 | 1,640 | 954 | |
| Sublease income | 662 | 484 | 348 | 357 | 366 | 337 | |
| Gross profit: | 7,697 | 1,157 | 890 | 13,191 | 1,640 | 954 | |
| Operating expenses | (24,337) | (22,653) | (22,356) | (23,138) | (19,247) | (35,982) | |
| Operating loss: | (16,640) | (21,496) | (21,466) | (9,947) | (17,607) | (35,028) | |
| Nonoperating income (expense) | 33,302 | (206) | (343) | (361) | (350) | (265) | |
| Investment income, nonoperating | 33,290 | 4 | 9 | 5 | 7 | 4 | |
| Other nonoperating income | 617 | 479 | 352 | 332 | 353 | 338 | |
| Interest and debt expense | (605) | (689) | (704) | (698) | (710) | (607) | |
| Income (loss) before gain (loss) on sale of properties: | 16,057 | (22,391) | (22,513) | (11,006) | (18,667) | (35,900) | |
| Other undisclosed net income | 605 | 698 | 710 | ||||
| Net income (loss): | 16,662 | (22,391) | (22,513) | (10,308) | (17,957) | (35,900) | |
| Other undisclosed net income attributable to parent | 689 | 704 | 607 | ||||
| Net income (loss) attributable to parent: | 16,662 | (21,702) | (21,809) | (10,308) | (17,957) | (35,293) | |
| Preferred stock dividends and other adjustments | (535) | (3,457) | |||||
| Net income (loss) available to common stockholders, diluted: | 16,662 | (21,702) | (21,809) | (10,308) | (18,492) | (38,750) | |
Comprehensive Income ($ in thousands)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | 16,662 | (22,391) | (22,513) | (10,308) | (17,957) | (35,900) | |
| Comprehensive income (loss): | 16,662 | (22,391) | (22,513) | (10,308) | (17,957) | (35,900) | |
| Other undisclosed comprehensive income, net of tax, attributable to parent | 689 | 704 | 607 | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | 16,662 | (21,702) | (21,809) | (10,308) | (17,957) | (35,293) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.